Ooi, Zhuan Shern * and Pang, Siew Wai * and Teow, Sin Yeang * (2022) RAS and BRAF genes as biomarkers and target for personalised colorectal cancer therapy: An update. The Malaysian Journal of Pathology, 44 (3). pp. 415-428. ISSN 0126-8635
Full text not available from this repository.Abstract
Colorectal cancer (CRC) remains among the most commonly diagnosed cancers and has been on the rise. It is also one of the most lethal diseases globally, being the third leading cause of cancerrelated death. Depending on the stages and disease conditions, CRC is treated by surgery, chemo-, radio-therapy, immunotherapy or in combination. However, these therapies have subpar results with unwanted side effects, hence continuous effort is ongoing to explore new type of therapeutic modalities. Among the sub-types of CRC, KRAS, BRAF and NRAS mutated CRC comprise approximately 43%, 10% and 3% of the total cases, respectively. These mutations are associated with tumour progression and anti-epidermal growth factor receptor (EGFR) treatment resistance. Due to their important role in CRC, these genes have thus become targets in the development of novel treatments. In this paper, we discuss the current and upcoming treatment on CRC by targeting these mutated genes, with more focus on KRAS and BRAF due to the higher occurrence of mutations in CRC.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | colorectal cancer; KRAS mutation; BRAF mutation; personalised therapy; molecular targets; biomarkers |
| Subjects: | Q Science > QH Natural history R Medicine > R Medicine (General) R Medicine > RC Internal medicine |
| Divisions: | Sunway University > School of Medical and Life Sciences [formerly School of Healthcare and Medical Sciences until 2020] > Department of Medical Sciences |
| Depositing User: | Ms Yong Yee Chan |
| Date Deposited: | 10 Aug 2024 04:43 |
| Last Modified: | 10 Aug 2024 04:43 |
| URI: | http://eprints.sunway.edu.my/id/eprint/3049 |
Actions (login required)
 |
View Item |
